Search results
22 gru 2021 · A 3-day course of remdesivir had an acceptable safety profile and prevented disease progression resulting in hospitalization among high-risk patients with Covid-19.
- Correspondence Mar 17, 2022 Outpatient Remdesivir to Prevent Progression to Severe Covid-19
Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to...
- Free Full Text
We conducted a double-blind, randomized, placebo-controlled...
- Editorial Jan 27, 2022 The Goldilocks Time for Remdesivir — Is Any Indication Just Right E.L. Heil and S. Kottilil
In a randomized, double-blind, placebo-controlled trial, it...
- Original Article Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma H. Tilly and Others
Diffuse large B-cell lymphoma (DLBCL) is typically treated...
- Original Article Cardiovascular and Cancer Risk With Tofacitinib in Rheumatoid Arthritis S.R. Ytterberg and Others
Tofacitinib is a targeted synthetic DMARD that selectively...
- Interactive Medical Case Up in The Air J.V. Loewenthal and Others
Case 3-2022: A 14-Year-Old Boy with Fever, Joint Pain, and...
- Editorial The Price of Freedom From Tricuspid Regurgitation J. Chikwe and M. Gaudino
From the Department of Cardiac Surgery, Smidt Heart...
- Perspective Please Don't Keep Me A. Drutchas
After her grandmother attempts suicide, a physician finds...
- Correspondence Mar 17, 2022 Outpatient Remdesivir to Prevent Progression to Severe Covid-19
Kluczowe wnioski. W uwzględnionych badaniach porównano stosowanie remdesiwiru wraz ze standardową opieką zdrowotną lub standardową opieką zdrowotną (z placebo lub bez niego) u hospitalizowanych chorych na COVID-19. Pacjenci hospitalizowani z umiarkowanym lub ciężkim przebiegiem COVID-19.
14 wrz 2021 · Here we report the results of the DisCoVeRy trial comparing remdesivir to control in hospitalised patients with COVID-19. Remdesivir administration was well tolerated but was neither associated with a better clinical outcome at day 15 and 29 nor with a faster viral clearance.
22 maj 2020 · We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract...
21 lut 2023 · This individual patient data meta-analysis showed that remdesivir reduced mortality in patients hospitalised with COVID-19 who required no or conventional oxygen support, but was underpowered to evaluate patients who were ventilated when receiving remdesivir.
19 lip 2023 · Recently, remdesivir treatment for 3 days in nonhospitalized participants showed a significant reduction in COVID-19–related hospitalization or all-cause death compared with placebo . Remdesivir is approved for the treatment of COVID-19 in pediatric and adult hospitalized and nonhospitalized patients in the United States, the European Union ...
19 cze 2024 · Update on efficacy of the approved remdesivir regimen for treatment of COVID-19: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials: Current Medical Research and Opinion: Vol 40 , No 8 - Get Access. Current Medical Research and Opinion Volume 40, 2024 - Issue 8. 85. Views. 0.
